Related references
Note: Only part of the references are listed.Abstract 2165: Structure activity relationship of a novel chemical class of Dyrk inhibitors.
Anne-Sophie Casagrande et al.
CANCER RESEARCH (2014)
Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition
Jing Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Identifying MicroRNA and mRNA Expression Profiles in Embryonic Stem Cells Derived from Parthenogenetic, Androgenetic and Fertilized Blastocysts
Xiang-Shun Cui et al.
JOURNAL OF GENETICS AND GENOMICS (2013)
Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
Heloisa P. Soares et al.
PLOS ONE (2013)
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Taru Muranen et al.
CANCER CELL (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics
Qingsong Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Craig P. Carden et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2
Jing Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
IKBKE Protein Activates Akt Independent of Phosphatidylinositol 3-Kinase/PDK1/mTORC2 and the Pleckstrin Homology Domain to Sustain Malignant Transformation
Jian-Ping Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Daina Z. Ewton et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
The kinase Mirk is a potential therapeutic target in osteosarcoma
Cao Yang et al.
CARCINOGENESIS (2010)
Targeting the PI3K signaling pathway in cancer
Kwok-Kin Wong et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species
Xiaobing Deng et al.
CANCER RESEARCH (2009)
Cancer Stem Cells and Aneuploid Populations within Developing Tumors Are the Major Determinants of Tumor Dormancy
Anjali P. Kusumbe et al.
CANCER RESEARCH (2009)
Insulin Receptor Substrate-2 Mediated Insulin-like Growth Factor-I Receptor Overexpression in Pancreatic Adenocarcinoma through Protein Kinase Cδ
Junhye Kwon et al.
CANCER RESEARCH (2009)
TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
Jeremy Copp et al.
CANCER RESEARCH (2009)
Mirk Regulates the Exit of Colon Cancer Cells from Quiescence
Kideok Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Mirk/Dyrk1B in cancer
Eileen Friedman
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow
C. Schindlbeck et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer
Kideok Jin et al.
CANCER RESEARCH (2007)
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer
Jeffrey A. Engelman
CLINICAL CANCER RESEARCH (2007)
HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells
Sebastian Kolb et al.
CANCER RESEARCH (2007)
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification
Riina Kuuselo et al.
CANCER RESEARCH (2007)
Primitive, quiescent and difficult to kill - The role of non-proliferating stem cells in chronic myeloid leukemia
David J. Barnes et al.
CELL CYCLE (2006)
The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma
XB Deng et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Phosphorylation of mammalian target of rapamycin (mTOR) at ser-2448 is mediated by p70S6 kinase
GG Chiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase
XB Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M
YL Zou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation
XB Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer
O Stoeltzing et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties
S Leder et al.
BIOCHEMICAL JOURNAL (2003)
Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas
KJ Stanton et al.
AMERICAN JOURNAL OF SURGERY (2003)
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
GJPL Kops et al.
NATURE (2002)
Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1α
S Lim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Control of cell cycle exit and entry by protein kinase B-regulated Forkhead transcription factors
GJPL Kops et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Share Paper
